Antibiotic vancomycin tested as PSC treatment – trial stopped early
NCT ID NCT03710122
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the antibiotic vancomycin, taken by mouth, is safe and effective for adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were randomly assigned to receive vancomycin or a placebo. The main goal was to see if vancomycin could lower a key liver enzyme (alkaline phosphatase) over 6 to 24 months. The trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vancomycin (an antibiotic taken by mouth)
What this could lead to
If it works, this could point toward a treatment to control PSC and reduce liver damage.
What could go wrong
The trial was terminated early, so results are limited. It is still unclear if vancomycin is truly effective for PSC, and antibiotics can cause side effects like gut issues or resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona State University
Tempe, Arizona, 85281, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85259, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States